Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia

MeSH terms

• Antimetabolites, Antineoplastic* / administration & dosage
• Antimetabolites, Antineoplastic* / adverse effects
• Azacitidine* / administration & dosage
• Azacitidine* / adverse effects
• Breast Neoplasms* / drug therapy
• Breast Neoplasms* / genetics
• Breast Neoplasms* / pathology
• Chromosome Deletion*
• Chromosomes, Human, Pair 12 / genetics*
• Chromosomes, Human, Pair 13 / genetics*
• Drug Resistance, Neoplasm* / drug effects
• Drug Resistance, Neoplasm* / genetics
• Female
• Humans
• Leukemia, Promyelocytic, Acute* / chemically induced
• Leukemia, Promyelocytic, Acute* / drug therapy
• Leukemia, Promyelocytic, Acute* / genetics
• Leukemia, Promyelocytic, Acute* / pathology
• Middle Aged
• Myelodysplastic Syndromes* / chemically induced
• Myelodysplastic Syndromes* / genetics
• Myelodysplastic Syndromes* / pathology
• Neoplasms, Second Primary* / drug therapy
• Neoplasms, Second Primary* / genetics
• Neoplasms, Second Primary* / pathology
• Translocation, Genetic*